Suboxone

Kuvaus

Suboxone (buprenorphine/naloxone) is a widely used medication for the maintenance treatment of opioid use disorder (OUD). It combines buprenorphine, a partial mu-opioid agonist, with naloxone, an opioid antagonist, in a 4:1 ratio. This formulation is designed to minimize abuse liability, especially when injected.

How Suboxone Works: Buprenorphine partially activates opioid receptors to suppress withdrawal symptoms and cravings without producing the full euphoric effects of stronger opioids. Naloxone remains largely inactive when taken sublingually as intended, but blocks opioid effects and can precipitate withdrawal if the medication is injected or misused.

Main Uses:

• Maintenance treatment of opioid dependence
• Part of a comprehensive medication-assisted treatment (MAT) program, including counseling and psychosocial support
• Often used after initial induction with buprenorphine monotherapy (e.g., Subutex)

Dosage and Administration Suboxone is administered sublingually (under the tongue) or buccally (inside the cheek) once daily. Typical maintenance doses range from 4mg/1mg to 24mg/6mg buprenorphine/naloxone per day, adjusted individually. Tablets or films must fully dissolve; do not swallow, chew, or cut. Treatment starts when moderate withdrawal symptoms appear.

Quality and Formulation Suboxone is available as sublingual tablets or orange-flavored films in strengths such as 2mg/0.5mg, 4mg/1mg, 8mg/2mg, and 12mg/3mg. Originally manufactured by Indivior (Reckitt Benckiser); generics are widely available. Produced under strict GMP standards with child-resistant packaging.

Warnings and Precautions Suboxone is a Schedule III controlled substance. It can cause respiratory depression, especially when combined with benzodiazepines, alcohol, or other CNS depressants. Common side effects include headache, nausea, constipation, sweating, insomnia, and mouth irritation.

Risk of dependence and withdrawal exists if stopped abruptly. Not recommended in severe hepatic impairment. Monitor for misuse or diversion. Patients should be warned against using other opioids while on Suboxone, as it can precipitate withdrawal. Pregnancy use requires careful risk-benefit assessment (neonatal opioid withdrawal syndrome possible).